The startup develops therapeutic drugs targeting cancer and respiratory diseases by utilizing a platform focused on synthetic lethality and DNA damage response mechanisms. This approach aims to create novel anticancer agents that effectively combat drug resistance, addressing significant gaps in current treatment options.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers develop resistance to existing therapies through DNA damage response (DDR) mechanisms, while other cancers are driven by mutations in oncogenes like RAS, creating a need for novel therapeutic targets and strategies. Current treatment options often fail to address these resistance mechanisms or effectively target mutated oncoproteins, leading to limited efficacy and poor patient outcomes. Additionally, there is a need for new therapies addressing tumor-intrinsic immune evasion and targeted antiviral agents for respiratory diseases.
Solution
Arum Therapeutics is a pharmaceutical company focused on discovering and developing innovative medicines based on synthetic small molecules to address unmet medical needs in oncology and respiratory diseases. The company utilizes a synthetic lethality (SL) platform targeting DNA damage response (DDR) mechanisms to develop anticancer agents that overcome drug resistance. Arum Therapeutics is also developing therapies targeting RAS mutations, tumor-intrinsic immune evasion, and targeted antiviral agents. Their approach aims to create novel therapeutics that can be used as mono- or combination therapies to improve patient outcomes.
Target Audience
The primary target audience includes patients with cancers exhibiting drug resistance or specific oncogene mutations, as well as individuals suffering from respiratory diseases like Asthma and COPD.
Features
- Synthetic lethality (SL) platform targeting DNA Damage Response (DDR) for oncology
- Development of inhibitors to overcome resistance to existing cancer therapies
- Programs targeting RAS mutations to combat cancer cell resistance and proliferation
- Development of immunotherapies to modulate anticancer immune functions
- Discovery of targeted antiviral agents for Asthma and COPD exacerbation
- Medicinal chemistry expertise in synthetic small molecules
- Pipeline includes programs in Hit Finding, Hit-to-Lead, and Lead Optimization phases